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incomplete revascularization is not consistent among the
trials. In spite of the above limitations, rSS may help us to
identify subset of patients at risk of adverse events
following PCI who might benefit from additional revascu-
larization if possible or by aggressive medical treatment and
close follow-up.
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Background: The effectiveness of durable polymer drug-
eluting stents comes at the expense of delayed arterial heal-
ing and subsequent late adverse events such as stent throm-
bosis (ST). We report the 4-year follow-up of an assessment of
biodegradable polymer-based drug-eluting stents, which aim
to improve safety by avoiding the persistent inflammatory
stimulus of durable polymers.
Methods: We did a multicentre, assessor-masked, non-
inferiority trial. Between Nov 27, 2006, and May 18, 2007,
patients aged 18 years or older with coronary artery disease
were randomly allocated with a computer-generated
sequence to receive either biodegradable polymer biolimus-
eluting stents (BES) or durable polymer sirolimus-eluting
stents (SES; 1:1 ratio). The primary endpoint was
a composite of cardiac death, myocardial infarction, or clini-
cally indicated target vessel revascularisation (TVR); patients
were followed-up for 4 years. Analysis was by intention to
treat. This trial is registered with ClinicalTrials.gov, number
NCT00389220.
Findings: 1707 patients with 2472 lesions were randomly
allocated to receive either biodegradable polymer BES (857
patients, 1257 lesions) or durable polymer SES (850
patients, 1215 lesions). At 4 years, biodegradable polymer
BES were non-inferior to durable polymer SES for the
primary endpoint: 160 (18.7%) patients versus 192 (22.6%)
patients (rate ratios [RR] 0.81, 95% CI 0.66e1.00, p for non-
inferiority <0.0001, p for superiority ¼ 0.050). The RR of
definite ST was 0.62 (0.35e1.08, p ¼ 0.09), which was largely
attributable to a lower risk of very late definite ST between
years 1 and 4 in the BES group than in the SES group (RR
0.20, 95% CI 0.06e0.67, p ¼ 0.004). Conversely, the RR of
definite ST during the first year was 0.99 (0.51e1.95;
p ¼ 0.98) and the test for interaction between RR of definite
ST and time was positive (Pinteraction ¼ 0.017). We recorded
an interaction with time for events associated with ST but
not for other events. For primary endpoint events associ-
ated with ST, the RR was 0.86 (0.41e1.80) during the first
year and 0.17 (0.04e0.78) during subsequent years
(Pinteraction ¼ 0.049).
Interpretation: Biodegradable polymer BES are non-inferior
to durable polymer SES and, by reducing the risk of cardiac
events associated with very late ST, might improve long-term
clinical outcomes for up to 4 years compared with durable
polymer SES.Clinical perspective
Durable polymers in the first generation drug-eluting stents
(DES) have been shown to be responsible for persistent
vascular inflammatory response and delayed arterial healing
with resultant late adverse events. The biodegradable
biolimus-eluting stent (BES) is designed in such a way that it
offers an attractive combination of controlled drug elusion in
parallel with biodegradation of the abluminal polymer into
inert monomers within 6e9 months and only a bare-metal
stent (BMS) remains thereafter. In the all-comer LEADERS
trial, the BES stent met the noninferiority composite
endpoint of death, myocardial infarction and target vessel
revascularization at 9 months (BES: 9% vs SES: 11%, p ¼ 0.39).
The study population was followed up further for 3 years for
the durability of the safety and efficacy outcomes. At the end
of 4 years, BES not only met the primary outcomes and was
also associated with lower incidence of very late definite
stent thrombosis (0.12%/year vs 0.6%/year). In the subgroup
analysis, BES showed a pronounced advantage in patients
with ST-elevation myocardial infarction. The notable
features of this study are: (1) the safety outcomes were
evident only after the first year that is after complete
degradation of the polymer e the proof of concept for the
biodegradable polymer, (2) long-term durability of the anti-
restenotic efficacy (3) higher incidence of definite ST in the
presence of long-term dual antiplatelet therapy in the SES
cohort e underlining the continued proneness of this stent
platform to very late thrombosis (4) even though the TLR, MI,
and primary composite endpoint were numerically better,
the study was not powered to show the superiority of BES
over SES. This was elegantly shown in the pooled analysis of
the individual patient data from three studies comparing
biodegradable polymer stents and durable polymer SES
(Stefanini GG, et al, Eur Heart J 2012). (5) Superior outcomes in
patients with STEMI, even though this study was not pow-
ered for this outcome. However, the COMFORTABLE AMI trial
presented in EuroPCR 2012 has shown excellent safety
outcomes for BES when compared to BMS with significantly
lower incidence of target vessel reinfarction, TVR, and ST at 1
year. In conclusion, long-term results from the LEADERS and
similar trials provide encouraging evidence for the clinical
use of biodegradable polymer stent platforms.
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Effectiveness of percutaneous coronary intervention (PCI) and
coronary artery bypass grafting (CABG) for the treatment of
patients with stable multi-vessel coronary artery disease is
i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 4 2 7e4 3 4 431a debatable issue. Weintraub and colleagues compared the
two strategies from observational registry data of over 180,000
patients from the American College of Cardiology Foundation
(ACCF) and the Society of Thoracic Surgeons (STS) Database
Collaboration (ASCERT study). This study included medicare
patients who were 65 years or older with stable multi-vessel
coronary artery disease and underwent a revascularization
procedure between January 2004 and December 2007 in U.S.
As expected, two groups had significant differences at
baseline. PCI group hadmore females and older patientswhile
CABG group had more patients with heart failure, diabetes,
hypertension, chronic lung disease, cerebrovascular disease,
history of smoking, or peripheral arterial disease. PCI group
patients had higher ejection fraction despite having history of
more acute coronary syndromes. Triple vessel disease was
more in CABG group and double vessel disease was more in
PCI group. In the PCI group, 78% received drug-eluting stents,
16% received bare metal stent and 6% had procedure without
any stent. These groups were adjusted using inverse proba-
bility weighting and after adjustment all clinical covariates
were well balanced. One year after the procedure, there was
no significant difference in the mortality between the CABG
and PCI groups (6.2% and 6.8% respectively). At 4 years,
however, CABG demonstrated a significantly lower adjusted
mortality than PCI (16.4% vs. 20.8%; risk ratio, 0.79; 95% CI,
0.76e0.82). The benefit of CABG was present across all
subgroups like age, diabetes, renal dysfunction, etc.
Major limitation of this study, as discussed by authors
and the accompanying editorial is the effect of unmeasured
confounders. Treatment selection usually involves a careful
clinical judgement that goes beyond statistical calculations
and a few measured variables. Adequate control of
confounders may not be possible in this kind of non-
randomized comparison and thus affecting the reliability
of the results. Another limitation is bias in the selection
of revascularization procedure as evident by the huge
difference in the unadjusted baseline characteristics of the
two groups. Various important clinical variables were not
reported in the databases such as, bleeding risk, stroke rate,
drug compliance, angiogram and completeness of revascu-
larization procedure.Perspective
In various clinical trials comparing the two revascularization
strategies, mortality advantage for CABG has been found in
some studies for patients with diabetes and complex coronary
artery disease. Themost contemporary SYNTAX trial provides
a comprehensive SYNTAX score to access the extent and
complexity of the coronary artery disease and is a useful tool
in decision making for the choice of revascularization
strategy. More light on this issue is expected from the recently
concluded FREEDOM trial that has studied the two strategies
in diabetic multi-vessel disease. Results of this trial are
expected later this year in the annual AHA meeting. One
important aspect that has not been addressed in the ASCERT
study is the impact of optimal medical therapy. As shown in
the COURAGE trial, optimal medical therapy is at least as good
as PCI in mortality reduction for patients with stable coronaryartery disease. Scientific advancements has not only resulted
in better revascularization strategies over the time but has
also contributed significantly to the medical management of
coronary artery disease. A more contemporary answer to this
debate is expected from the proposed ISCHEMIA trial which
will compare angiography and revascularization plus optimal
medical therapy with the conservative strategy of optimal
medical therapy only in stable coronary artery disease.
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Objectives: This study investigated the effect of catheter-
based renal sympathetic denervation (RD) on left ventricular
hypertrophy (LVH) and systolic and diastolic function in
patients with resistant hypertension.
Background: LVH and diastolic dysfunction are associated
with elevated sympathetic activity and increased morbidity
and mortality. The effect of RD on LVH and LV function is
unclear.
Methods: Forty-six patients underwent bilateral RD, and 18
patients served as controls. Transthoracic echocardiography
was performed at baseline, and after 1 month and 6 months.
Results: Besides significant reduction of systolic and dia-
stolic blood pressure at 1 month and 6 months, RD signifi-
cantly reduced mean interventricular septum thickness from
14.1  1.9 mm to 13.4  2.1 mm and 12.5  1.4 mm (p ¼ 0.007),
and LVmass index from 53.9  15.6 g/m2 (112.4 33.9 g/m2) to
47.0  14.2 g/m2 (103.6  30.5 g/m2) and 44.7  14.9 g/m2
(94.9  29.8 g/m2) (p < 0.001) at 1 month and 6 months,
respectively. The mitral valve lateral E/E’ decreased after RD
from 9.9  4.0 to 7.9  2.2 at 1 month and 7.4  2.7 at 6 months
(p < 0.001), indicating reduction of LV filling pressures. Iso-
volumic relaxation time shortened (baseline 109.1  21.7 ms
vs. 85.6  24.4 ms at 6 months, p < 0.006), whereas ejection
fraction significantly increased after RD (baseline: 63.1  8.1%
vs. 70.1 11.5% at 6 months, p< 0.001). No significant changes
were obtained in control patients.
Conclusions: Besides the known effect on blood pressure,
our study showed for the first time that RD significantly
reduces LV mass and improves diastolic function, which
might have important prognostic implications in patients
with resistant hypertension at high cardiovascular risk.Perspective
Chronic activation of the sympathetic nervous system is
involved in the development and maintenance of arterial
